1.	Evaluation of RUX and AZA Combination as a Therapy For Patients With Myelofibrosis And Myelodysplastic Syndrome/ Myeloproliferative Neoplasm Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2012-0737, NCT01787487
2.	Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MCC-17114, NCT01702064
3.	Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD) Phase: Phase II, Phase I Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: 2012-0697, NCT01751425
4.	A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib Phase: Phase II, Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: MCC-17259, NCT01776723
5.	Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 19 and over Sponsor: Other Protocol IDs: 283-11, NCT01431209
6.	Ruxolitinib in Patients With Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 12-024, NCT01562873
7.	Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: INCB18424-258, NCT01348490
8.	Ruxolitinib for Adult T-Cell Leukemia Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 130006, 13-C-0006, NCT01712659
9.	Ruxolitinib in Estrogen Receptor Positive Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UPCC 02112, NCT01594216
10.	Ruxolitinib Prior to Transplant in Patients With Myelofibrosis Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 70 Sponsor: NCI, Other Protocol IDs: GCO 12-1809, MPD-RC 114, NCT01790295
11.	INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Over 12 months to 21 Sponsor: NCI, Other Protocol IDs: CDR0000680970, COG-ADVL1011, ADVL1011, NCT01164163
12.	An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: INCB 18424-144, NCT01822756